Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 120, Issue 4, Pages 963-972Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI41350
Keywords
-
Categories
Funding
- NIH [NIH-HD-16229, NIH-HD-16272, NIH-HD-07945]
- Burroughs Wellcome Career Award in the Biomedical Sciences
- Dan L. Duncan Cancer Center
- Caroline Weiss Law Fund for Molecular Medicine
Ask authors/readers for more resources
The classical view of ovarian follicle development is that it is regulated by the hypothalamic-pituitary-ovarian axis, in which gonadotropin-releasing hormone (GnRH) controls the release of the gonadotropic hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and that ovarian steroids exert both negative and positive regulatory effects on GnRH secretion. More recent studies in mice and humans indicate that many other intra-ovarian signaling cascades affect follicular development and gonadotropin action in a stage- and context-specific manner. As we discuss here, mutant mouse models and clinical evidence indicate that some of the most powerful intra-ovarian regulators of follicular development include the TGF-beta/SMAD, WNT/FZD/beta-catenin, and RAS/ERK1/2 signaling pathways and the FOXO/FOXL2 transcription factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available